LYG-409 is an orally active degrader of GSPT1 that demonstrates potent antitumor activity in vivo, with tumor growth inhibition (TGI) rates of 94.34% in acute myeloid leukemia and 104.49% in prostate cancer models. In vitro, LYG-409 inhibits KG-1 cells through GSPT1 degradation, with an IC₅₀ of 9.50 nM and a DC₅₀ of 7.87 nM.
LYG-409 is an orally active degrader of GSPT1 that demonstrates potent antitumor activity in vivo, with tumor growth inhibition (TGI) rates of 94.34% in acute myeloid leukemia and 104.49% in prostate cancer models. In vitro, LYG-409 inhibits KG-1 cells through GSPT1 degradation, with an IC₅₀ of 9.50 nM and a DC₅₀ of 7.87 nM.
Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 1 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula: